The FDA has granted accelerated approval for Novartis’ chimeric antigen receptor (CAR)-T cell drug Kymriah (tisagenlecleucel) for the treatment of patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The approval was supported by data from a 90-participant clinical trial in which 68 percent of patients experienced a complete response.
Under the terms of the accelerated approval, the company must conduct one or more confirmatory clinical trials to demonstrate the treatment’s benefit.
Kymriah is also approved for patients up to 25 years old who have B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse and for patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.